NICE issues recommendation for dapagliflozin-insulin therapy in type 1 diabetes

The U.K. National Institute for Health and Care Excellence (NICE) has issued new guidance on the combined usage of dapagliflozin and insulin for treating patients with type 1 diabetes inadequately controlled by insulin alone.

In a review of clinical trials, NICE found that dapagliflozin plus insulin conferred small benefits in hemoglobin A_1c, weight loss, and quality of life, compared with insulin alone. These benefits translated to a reduced risk of long-term complications over the lifetime of the patient.

In the new NICE guideline, dual treatment with dapagliflozin and insulin in adults with type 1 diabetes and a body mass index greater than 27 kg/m² is recommended only when they are receiving insulin doses of more than 0.5 units/kg per day; have undergone an evidence-based, quality-assured education program; and are supervised by a physician specializing in endocrinology and diabetes.

Hemoglobin A_1c levels should be assessed after 6 months and at regular intervals after that; if glycemic control is not improved, dapagliflozin should be stopped, as there is an increased risk of diabetic ketoacidosis.

Find the full technology appraisal guidance on the NICE website.

[email protected]

The U.K. National Institute for Health and Care Excellence (NICE) has issued new guidance on the combined usage of dapagliflozin and insulin for treating patients with type 1 diabetes inadequately controlled by insulin alone.

In a review of clinical trials, NICE found that dapagliflozin plus insulin conferred small benefits in hemoglobin A_1c, weight loss, and quality of life, compared with insulin alone. These benefits translated to a reduced risk of long-term complications over the lifetime of the patient.

In the new NICE guideline, dual treatment with dapagliflozin and insulin in adults with type 1 diabetes and a body mass index greater than 27 kg/m² is recommended only when they are receiving insulin doses of more than 0.5 units/kg per day; have undergone an evidence-based, quality-assured education program; and are supervised by a physician specializing in endocrinology and diabetes.

Hemoglobin A_1c levels should be assessed after 6 months and at regular intervals after that; if glycemic control is not improved, dapagliflozin should be stopped, as there is an increased risk of diabetic ketoacidosis.

Find the full technology appraisal guidance on the NICE website.

[email protected]

The U.K. National Institute for Health and Care Excellence (NICE) has issued new guidance on the combined usage of dapagliflozin and insulin for treating patients with type 1 diabetes inadequately controlled by insulin alone.

In a review of clinical trials, NICE found that dapagliflozin plus insulin conferred small benefits in hemoglobin A_1c, weight loss, and quality of life, compared with insulin alone. These benefits translated to a reduced risk of long-term complications over the lifetime of the patient.

In the new NICE guideline, dual treatment with dapagliflozin and insulin in adults with type 1 diabetes and a body mass index greater than 27 kg/m² is recommended only when they are receiving insulin doses of more than 0.5 units/kg per day; have undergone an evidence-based, quality-assured education program; and are supervised by a physician specializing in endocrinology and diabetes.

Hemoglobin A_1c levels should be assessed after 6 months and at regular intervals after that; if glycemic control is not improved, dapagliflozin should be stopped, as there is an increased risk of diabetic ketoacidosis.

Find the full technology appraisal guidance on the NICE website.

[email protected]